Almirall's Ilumetri® (tildrakizumab) significantly improves wellbeing for patients1 and their relatives2 in moderate-to-severe plaque psoriasis

Almirall's Ilumetri® (tildrakizumab) significantly improves wellbeing for patients1 and their relatives2 in moderate-to-severe plaque psoriasis •      Interim data from the POSITIVE study, presented at the EADV, revealed that tildrakizumab not only significantly improved patien...

Related Keywords

Germany ,France ,Spain ,Austria ,Switzerland ,Barcelona ,Comunidad Autonoma De Cataluna ,Berlin ,Italy ,Netherlands ,United Kingdom ,Belgium ,Spanish ,German ,Almirall Ilumetri ,Volker Koscielny ,Ulrich Mrowietz ,Matthias Augustin ,World Health Organization Wellbeing Index ,University Medical Center Schleswig Holstein ,Venereology Congress ,Founder Of The Psoriasis Center ,European Association Of Dermatology ,Spanish Stock Exchange ,European Academy Of Dermatology ,European Association ,Psoriasis Center ,University Medical Center ,Chief Medical Officer ,Noble Purpose ,European Academy ,Safe Treatment ,Psoriatic Disease ,Real World Prospective Cohort Study ,